TFCP2 and melanoma: To support whether the FGF1 binding defect was specific to human melanoma cells, we knocked down TFCP2 expression in a panel of patient-derived malignant melanoma tumor lines with diverse genotypes (SkMel2, SkMel5, SkMel28, and UACC62).